Subject: ILC 2021: call for abstracts on viral hepatitis
From: EASL Office <[email-masked]>
To: [email-masked]
Date: Tue, 06 Apr 2021 13:21:35 +0000

Second call for regular and high-profile late-breaker abstracts - 10-27 April

6 April 2021

Read online

Last chance to deliver your research in front of

the global liver community at ILC 2021

Thousands of delegates from all corners of the world have already registered, and many of them are interested in viral hepatitis! Be sure to not miss this last chance to share your research with the global liver community.

Submit your regular or high-profile late-breaker abstract now and connect with your peers! Only by working hand in hand, can we reach our common goal of beating liver disease together.

Submit your abstract 10–27 April

Submit your regular or high-profile late-breaker abstract

Your research is essential to us beating liver disease together. Are you or your colleagues doing exciting research? Does your company have revealing late-breaker research data from clinical trials to present?

Let the global liver community hear about your latest findings. Make your mark by submitting your abstract to ILC 2021.

ABSTRACT CATEGORIES

Viral hepatitis A, B, C, D, E: Virology

Viral hepatitis A/E: Clinical aspects

Viral hepatitis B/D: Clinical aspects except therapy

Viral hepatitis B/D: Therapy

Viral hepatitis C: Clinical aspects except therapy

Viral hepatitis C: Post-SVR and long-term follow-up

Viral hepatitis C: Therapy and resistance

Submit your abstract

Interested in submitting an abstract on a different topic? Read more.

Discover key sessions on viral hepatitis at ILC 2021

Research Think Tank:

Understanding immunological and virologic responses in the liver to cure HBV infections

Chaired by: Tobias Böttler (Germany) & Fabien Zoulim (France)

Meet the Experts 1:

Hepatitis C treatment: Are there remaining challenges?

Andrea Cox (USA) & Graham Foster (United Kingdom)

Meet the experts 2:

HBV stopping NUCs before HBs antigens loss

George Papatheodoridis (Greece) & Florian van Bömmel (Germany)

Meet the experts 3:

Management of fulminant and chronic hepatitis E

Harry Dalton (United Kingdom) & Sven Pischke (Germany)

Public health session:

Viral hepatitis elimination: Assessing the progress in 2021

Joint EASL–CDC, ECDC, WHO symposium

Chair: Philippa Easterbrook (Switzerland)

4 Abstract sessions

Interactive session 1:

From checkpoint-blockade to immuno-suppressants: Management of viral hepatitis in patients with immuno-modulators

Chaired by: Harry Janssen (Canada) & Pietro Lampertico (Italy)

Interactive session 2:

New HBV biomarkers: Predicting outcomes and guiding management

Chaired by: Geoffrey Dusheiko (United Kingdom) & Ulrike Protzer (Germany)

Discover the Viral Hepatitis track at ILC 2021

ILC 2021 registration

Those abstract presenters who took part in the second round of abstract submission will have ten days after receiving their notification on 18 May to register with early fees.

EASL members will benefit from special registration fees. If you are not a member yet, you can become an EASL member now. It only takes a couple of minutes to fill in the form and start enjoying the numerous benefits of membership.

Mark your calendar

Register now

Get ready for ILC 2021

Visit our eLearning hub, EASL Campus. Create a free account or use the one you have and learn from over 880 resources on viral hepatitis. Start your EASL Campus experience and enjoy reading.

Discover the resources

Download the EASL app

Access event info, EASL Campus and stay informed with the latest messages and news.

For the latest on EASL events, follow us on Twitter

@EASLnews and @EASLedu

Share with a friend or colleague

You received this email, because in your previous interaction with EASL, you indicated your speciality and areas of particular interest. To update your preferences, please go to your MyEASL profile.

EASL, The Home of Hepatology

7 rue Daubin, 1203 Geneva, Switzerland

+41 22 807 03 60

www.easl.eu

[email-masked]

Update your preferences or unsubscribe